Arca
Skip to content
Tools
Tools

CXCR2: C-X-C chemokine receptor type 2

Receptor for interleukin-8 which is a powerful neutrophil chemotactic factor.

  • Drugs that act on it: 5
  • Approved: 0
  • In phases 1 to 3: 5
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on CXCR2, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 5

Approved0

    Phase 32

    • Ladarixin
    • Reparixin

    Phase 23

    • Danirixin
    • Elubrixin
    • Navarixin anhydrous

    Phase 10

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 3 of 5 act as: Interleukin-8 receptor B antagonist; the rest name their own mechanism.
      LadarixinPhase 3Dompé FarmaceuticiSmall moleculeModulatorInterleukin-8 receptor B modulator1
      ReparixinPhase 3Dompé FarmaceuticiSmall moleculeModulatorInterleukin-8 receptor B modulator1
      DanirixinPhase 2GSKSmall moleculeAntagonist0
      ElubrixinPhase 2GSKSmall moleculeAntagonist0
      Navarixin anhydrousPhase 2Merck & Co. (MSD)Small moleculeAntagonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 2 in all, from ClinicalTrials.gov.
      Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)ReparixinPhase 2RecruitingIcahn School of Medicine at Mount SinaiApr 28, 2023
      Ladarixin With Sotorasib in Advanced NSCLCLadarixinPhase 1RecruitingNYU Langone HealthApr 18, 2023

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • WHIM syndrome 20.59
      • Autosomal recessive severe congenital neutropenia due to CXCR2 deficiency0.37
      • Crohn disease0.36
      • Type 1 diabetes mellitus0.30
      • Triple-negative breast carcinoma0.13

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2434, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P25025, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.